Researchers from Stanford University have published an article on the discovery of novel analogues of ponatinib that retained antitumor efficacy with substantially reduced cardiotoxicity.
Lift Biosciences Ltd. has shown that its first-in-class cell therapy destroyed on average over 90% of the tumoroid in a PDX (patient-derived xenograft) organoid across five solid tumor types, including bladder cancer, rectal cancer, colorectal cancer, gastric cancer and squamous cell non-small-cell lung cancer (NSCLC).
Boehringer Ingelheim Pharma GmbH & Co KG has presented data on the identification of several potent and selective tyrosine kinase inhibitors (TKIs) of HER2 that are highly active against its oncogenic exon 20 YVMA insertion mutant (HER2 YVMA), which is the most prevalent HER2 exon 20 mutation in non-small-cell lung cancer (NSCLC).
Transcenta Holding Ltd. has received IND clearance from the FDA for TST-003, its first-in-class, high-affinity, humanized monoclonal antibody targeting gremlin-1.
The design of genetically modified exosomes that combine multiple targets killed cancer cells and conferred immunity against them. Scientists at the University of Southern California (USC) applied bioengineering techniques to introduce up to four antitumor functions in the same type of extracellular vesicles and destroy EGFR-positive triple-negative breast cancer (TNBC) tumor cells.
Rubius Therapeutics Inc. is taking a giant step back so that it can attempt taking a few steps forward. The company said it’s restructuring to focus on taking its Rubius Erythrocyte Design (RED) cell therapeutics platform from what it considers a good thing and turn it into a better one. Rubius engineers red blood cells to become cancer fighters but a lack of progress and the lure of similar but new technology could lead to bigger and better results.
Rayzebio Inc. raised $160 million in a series D round and unveiled its lead targeted radiopharmaceutical drug candidate, RYZ-101, which has entered clinical development in patients with gastroenteropancreatic neuroendocrine tumors expressing the somatostatin receptor type 2.
Shanghai Junshi Biosciences Co. Ltd. plans to raise up to ¥3.969 billion (US$570 million) by issuing no more than 70 million A shares to target subscribers on the Shanghai STAR Market.
Genexine Co. Ltd.’s DNA vaccine, GX-188E, showed potential in extending overall survival in patients with advanced cervical cancer in a phase II study when given in combination with Merck & Co. Inc.’s anti-PD-1 therapy, Keytruda (pembrolizumab). The Seoul, Korea-based company analyzed 60 patients with human papillomavirus (HPV)-16 or HPV-18-positive advanced cervical cancer who had progressed after standard-of-care therapy.
RSS
